Targeting epigenetic pathways has gained momentum as a therapeutic strategy in cancer. DNA methylation inhibitors have shown substantial activity in hematologic malignancies and two of them, azacytidine and 5- aza-2'-deoxycytidine (DAC) are now FDA approved for the treatment of the myelodysplastic syndrome (MDS). Histone deacetylase inhibitors (HDACi) have shown definite though more modest activity in hematologic neoplasia as well. There is in-vitro synergy between these two epigenetic pathways, at least at the level of gene reactivation. In a randomized phase III study of DAC (the most potent DMA methylation inhibitor available), we found that methylation decreases in the treated arm while it increases in the supportive care arm, and responders had more CpG island hypomethylation than non-responders. In a subsequent randomized phase II study, we identified a dose schedule that results in a complete remission (CR) rate of about 40% in MDS (by IWG criteria). Responses were associated with P15 induction, and patients with the highest levels of P15 after treatment were most likely to achieve a CR. We recently completed a phase I study combining DAC with valproic acid (VPA), an orally available HDACi, initially approved as an anti-seizure medication but that also has demonstrated anti-neoplastic activity. The DAC/VPA combination is safe and results in clinical responses in relapsed/refractory hematologic malignancies. In-vitro data showed histone hyperacetylation, a molecular phenomenon not observed after single agent DAC as well as more pronounced activation of P15 following combination therapy. These data led us to suggest the hypothesis that combined epigenetic therapy with DAC+VPA is more effective molecularly and clinically than DAC alone in the treatment of MDS. To test this hypothesis, we propose the following specific aims: (i) A randomized phase II clinical trial of DAC+VPA compared to DAC alone in MDS, with primary clinical endpoints of efficacy (CR, survival) and toxicity, (ii) The combination of DAC+VPA will be more effective at activating silenced gene expression (as measured by a panel of genes tested by qPCR, including P15) and (iii) CpG island methylation (as measured by pyrosequencing of a panel of genes) will decrease after treatment and correlate with responses to the combination. This grant will support the first testing, in a randomized setting, of combined epigenetic therapy, with both molecular and clinical endpoints. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA121104-01A2
Application #
7299658
Study Section
Clinical Oncology Study Section (CONC)
Program Officer
Merritt, William D
Project Start
2007-09-01
Project End
2012-07-31
Budget Start
2007-09-01
Budget End
2008-07-31
Support Year
1
Fiscal Year
2007
Total Cost
$292,600
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Raynal, Noël J-M; Da Costa, Elodie M; Lee, Justin T et al. (2017) Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome. Mol Cancer Ther 16:397-407
Kelly, A D; Kroeger, H; Yamazaki, J et al. (2017) A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome. Leukemia 31:2011-2019
Werner, Rachael J; Kelly, Andrew D; Issa, Jean-Pierre J (2017) Epigenetics and Precision Oncology. Cancer J 23:262-269
Issa, Jean-Pierre J (2017) Introduction: Cancer as an Epigenetic Disease. Cancer J 23:255-256
Yamazaki, Jumpei; Taby, Rodolphe; Jelinek, Jaroslav et al. (2015) Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia. J Natl Cancer Inst 108:
Yamazaki, Jumpei; Jelinek, Jaroslav; Lu, Yue et al. (2015) TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia. Cancer Res 75:2833-43
Issa, Jean-Pierre J (2013) The myelodysplastic syndrome as a prototypical epigenetic disease. Blood 121:3811-7
Yamazaki, Jumpei; Estecio, Marcos R; Lu, Yue et al. (2013) The epigenome of AML stem and progenitor cells. Epigenetics 8:92-104
Yamazaki, Jumpei; Issa, Jean-Pierre J (2013) Epigenetic aspects of MDS and its molecular targeted therapy. Int J Hematol 97:175-82
Yamazaki, Jumpei; Taby, Rodolphe; Vasanthakumar, Aparna et al. (2012) Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 7:201-7

Showing the most recent 10 out of 16 publications